Please use this identifier to cite or link to this item: http://dx.doi.org/10.25673/110442
Title: Translational analysis and final efficacy of the AVETUX trial - : avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
Author(s): Tintelnot, JosephLook up in the Integrated Authority File of the German National Library
Ristow, InkaLook up in the Integrated Authority File of the German National Library
Sauer, Markus
Simnica, Donjete
Schultheiß, Christoph
Scholz, RebekkaLook up in the Integrated Authority File of the German National Library
Goekkurt, Eray
Wenserski, LisaLook up in the Integrated Authority File of the German National Library
Willscher, Edith
Paschold, Lisa
Lorenzen, SylvieLook up in the Integrated Authority File of the German National Library
Riera Knorrenschild, JorgeLook up in the Integrated Authority File of the German National Library
Depenbusch, ReinhardLook up in the Integrated Authority File of the German National Library
Ettrich, Thomas J.Look up in the Integrated Authority File of the German National Library
Dörfel, Steffen
Al-Batran, Salah-Eddin
Karthaus, MeinolfLook up in the Integrated Authority File of the German National Library
Pelzer, UweLook up in the Integrated Authority File of the German National Library
Hinke, Axel
Bauer, Marcus
Massa, Barbara
Seliger, BarbaraLook up in the Integrated Authority File of the German National Library
Wickenhauser, Claudia
Bokemeyer, CarstenLook up in the Integrated Authority File of the German National Library
Hegewisch-Becker, SusannaLook up in the Integrated Authority File of the German National Library
Binder, MaschaLook up in the Integrated Authority File of the German National Library
Stein, AlexanderLook up in the Integrated Authority File of the German National Library
Issue Date: 2022
Type: Article
Language: English
Abstract: Introduction: In metastatic colorectal cancer (mCRC), the efficacy of immune checkpoint blockade (ICB) has so far been limited to patients with microsatellite instability high tumors (MSI-H). Unfortunately, most mCRC patients suffer from non-immunogenic microsatellite stable (MSS) tumors. Therefore, new combinatorial strategies are urgently needed to enhance the immunogenicity of MSS tumors to finally increase the number of patients benefiting from ICB. Methods: The AVETUX trial aimed to combine the PD-L1 antibody avelumab with the standard of care chemotherapy combination FOLFOX and the anti-EGFR antibody cetuximab. Furthermore, we performed a central radiological review of the pre- and on-treatment computed tomography scans to better define the individual response to treatment. Results and Discussion: In total, 43 patients were treated of which 39 patients were confirmed as RAS/BRAF wildtype in central tissue review and finally response evaluated. A final progression-free survival (PFS) of 11.1 (range: 0.8 to 22.3 months) and a herein updated final overall survival (OS) of 32.9 months (range: 0.8 to 47.1 months) was reached. We observed a strong median depth of response of 67.5% tumor shrinkage and deepness of response correlated significantly with survival. On the other hand, early tumor shrinkage was not an indicator of better outcome at a cut-off of 20% (median values). In a next step, we correlated the individual best radiological response with potential ICB response biomarkers and found that the clonality and diversity, but not frequency of tumor infiltrating lymphocytes (TiLs) and peripheral blood mononuclear cells (PBMCs), strongly correlated with response. In summary, we report the final overall survival of the AVETUX trial and propose T cell clonality and diversity as a potential marker to predict response to chemo-immunotherapy combinations in MSS mCRC by performing a central radiological review.
URI: https://opendata.uni-halle.de//handle/1981185920/112397
http://dx.doi.org/10.25673/110442
Open Access: Open access publication
License: (CC BY 4.0) Creative Commons Attribution 4.0(CC BY 4.0) Creative Commons Attribution 4.0
Journal Title: Frontiers in oncology
Publisher: Frontiers Media
Publisher Place: Lausanne
Volume: 12
Original Publication: 10.3389/fonc.2022.993611
Appears in Collections:Open Access Publikationen der MLU

Files in This Item:
File Description SizeFormat 
fonc-12-993611.pdf1.29 MBAdobe PDFThumbnail
View/Open